Endpoints News

The biopharma world is here. Get the industry’s most comprehensive daily news reports at

[Endpoints News @endpts]

In this week’s Peer Review: ex-iTeos CEO Michel Detheux takes the helm at GSK neuro partner Muna Therapeutics, Srishti Gupta returns as CEO at NovaBridge Biosciences and Genentech loses another veteran scientist as Eric Stefanich retires. https://t.co/kQPjAd9QHc

[Endpoints News @endpts]

Celea raised $180M to advance its idiopathic pulmonary fibrosis drug into Phase 3 testing, following fellow PureTech spinouts Karuna and Seaport. https://t.co/61twiIbSHg

[Endpoints News @endpts]

Revolution Medicines is moving its two-drug KRAS combination into Phase 3 testing for pancreatic cancer, after early data showed responses in half of second-line patients. https://t.co/bBbhAQ54XF

[Endpoints News @endpts]

BrightGene's obesity shot showed strong weight loss data in China, outpacing Lilly's Zepbound in the same market as it nears approval there. https://t.co/RsuOxr44mG

[Endpoints News @endpts]

Roche's divarasib beat Amgen's and Bristol Myers' drugs in a head-to-head Phase 3 lung cancer trial, improving both survival measures. https://t.co/2YG9LGzG9M

[Endpoints News @endpts]

Orca Bio wins FDA approval for its cell therapy aimed at better transplant outcomes.
https://t.co/TRS9FWUzay

[Endpoints News @endpts]

BridgeBio raises $1B ahead of three more drug launches.
https://t.co/TSyUpKtgwJ

[Endpoints News @endpts]

A strong June pushes biotech megarounds higher in the first half of 2026.
https://t.co/cFPcShNVEy

[Endpoints News @endpts]

Ipsen adds a kidney infection drug with its acquisition of Memo Therapeutics.
https://t.co/vDtwPBN05C

[Endpoints News @endpts]

Abivax says new trial data show cancer cases in its ulcerative colitis drug fall within the expected range, easing safety concerns that surfaced earlier this month. https://t.co/0y8ruDgJ43

[Andrew Dunn @AndrewE_Dunn]

NEW: Anthropic just announced a new product in Claude Science, aiming to achieve a Code-like vision for bioscientists

I talked with Eric Kauderer-Abrams on the launch, as well as what that Coefficient Bio acquisition was all about: https://t.co/NRgXm9kf2E

[Endpoints News @endpts]

Anthropic is launching Claude Science, an AI workbench for scientific research, in its biggest push into biopharma yet, debuting alongside leaders from Novartis, Bristol Myers Squibb and Genentech. https://t.co/WpQmxo1JnH

[Endpoints News @endpts]

Virtual mental health companies are racing to build their own therapy chatbots, but they disagree on a key question: whether to train the AI on real patient sessions or on synthetic conversations that never happened. https://t.co/8fFT73fESj

[Zach Brennan @ZacharyBrennan]

FDA's acting director of cell and gene therapies Vijay Kumar tells me he's not being pushed out as the super office chief and one year was enough - he's looking for new internal FDA and external positions - https://t.co/NkHPh0wvKo

[Endpoints News @endpts]

The New England Journal of Medicine has retracted pivotal data for Amgen's Tavneos, adding to the autoimmune drug's troubles as US and European regulators move to pull it from the market. https://t.co/rFX0hODsIo

[Endpoints News @endpts]

Exclusive: The House Select Committee on China is questioning Bristol Myers Squibb and Pfizer over their use of clinical trial sites in China, including facilities tied to the Chinese military and the Xinjiang region. https://t.co/CXSGOvfzai

[Endpoints News @endpts]

Zymeworks CEO makes the case for the $929M Theravance deal.
https://t.co/F11yIBXUeh

[Endpoints News @endpts]

J&J's John Reed on the R&D model, oncology dealmaking and what's next for the pipeline.
https://t.co/tAggoQoBQv

[Drew Armstrong @ArmstrongDrew]

Are pharma's China deals the new tax inversions?

Today I wrote about one of my earliest beats in healthcare: M&A transactions that let US companies flip their tax jurisdiction to low-cost Ireland... until Congress and the Obama admin got fed up: https://t.co/PknyEyXOEu

[Endpoints News @endpts]

Ipsen pays $450M upfront for blood cancer biotech Kartos Therapeutics.
https://t.co/jNZhow3IZp